Form 8-K - Current report:
SEC Accession No. 0001104659-24-105282
Filing Date
2024-10-02
Accepted
2024-10-02 11:16:04
Documents
14
Period of Report
2024-09-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2425381d1_8k.htm   iXBRL 8-K 44826
2 EXHIBIT 99.1 tm2425381d1_ex99-1.htm EX-99.1 32657
  Complete submission text file 0001104659-24-105282.txt   256302

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acur-20240930.xsd EX-101.SCH 3021
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acur-20240930_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acur-20240930_pre.xml EX-101.PRE 22363
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2425381d1_8k_htm.xml XML 3576
Mailing Address 616 N. NORTH COURT, SUITE 120 . PALATINE IL 60067
Business Address 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 847-705-7709
ACURA PHARMACEUTICALS, INC (Filer) CIK: 0000786947 (see all company filings)

EIN.: 110853640 | State of Incorp.: NY | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-10113 | Film No.: 241345823
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)